|
Table of Contents
Director’s Message
Staff Profiles
Program Description
Program Information
Guidelines for Application
Preceptorships
Post-Fellowship Employment
Life Outside the NCI
|
2007 Application Catalog
Preceptorships - Division of Cancer Prevention
Organ Systems Research Groups
The Lung and Upper Aerodigestive Cancer Research Group promotes and supports research targeting the early detection and prevention of cancer arising within the lung and upper aerodigestive tract. Collaborative research is conducted with extramural and intramural NCI staff, with emphasis on Phase II clinical trials of novel chemopreventive agents in individuals at high risk for cancers of these sites. Optimization of trial design, identification/validation of surrogate endpoint biomarkers, and integration of new imaging modalities into chemoprevention trials are ongoing research priorities.
Chief: Eva Szabo, M.D.
Potential Preceptor:
Eva Szabo, M.D.
Design and conduct of clinical trials to assess efficacy of chemopreventive strategies in the lung and upper aerodigestive tract.
- Design of clinical studies to test novel chemoprevention agents.
- Assessment of recruitment and retention problems in chemoprevention studies in former smokers and development of strategies to ameliorate this problem.
- Surrogate endpoint biomarker identification and validation in lung and head and neck chemoprevention trials - methodologies, retrospective analyses, prospective trial design.
Jason S. Vourlekis, M.D.
My interests are lung cancer prevention, early lung carcinogenesis, and COPD.
- Radiographic emphysema as a predictor of lung cancer risk: within the confines of the NLST, we plan to quantify baseline radiographic emphysema on the enrollment CT, and evaluate it as a predictor of lung cancer risk.
- C-reactive protein as a predictor of lung cancer mortality: the inflammation hypothesis suggests that chronic inflammation may be the reason that COPD is associated with a 2-4-fold increased risk of lung cancer after controlling for smoking. We hope to test this hypothesis by examining CRP as a predictor of lung cancer mortality using data from NHANES I.
|
